ArticleFrontiers in oncology2025
"Is the incidence of non-epithelial ovarian tumors on the rise? insights from a Tunisian tertiary center".
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-epithelial ovarian tumors (NEOTs), mainly germ cell and sex cord-stromal tumors, are rare entities that pose diagnostic and therapeutic challenges due to their heterogeneity and often nonspecific presentation. This study aimed to describe the epidemiological, clinical, pathological, and surgical characteristics of NEOTs managed at Charles Nicolle University Hospital, Tunis, over a five-year period. Materials and methods: We conducted a retrospective descriptive study including 48 patients operated for NEOTs between January 2020 and December 2024. Clinical, radiological, surgical, and pathological data were analyzed. Results: NEOTs represented 20.9% (48/229) of ovarian tumors. Median age at diagnosis was 35 years (IQR 28-51). Germ cell tumors accounted for 68.8% and sex cord-stromal tumors for 29.1%. Malignant tumors were rare (6.3%), all stage IA. Conservative surgery was performed in 56.2%, predominantly in germ cell tumors, while laparotomy was the main approach (87.5%). Compared with germ cell tumors, sex cord-stromal tumors occurred in older (median 51 vs. 30 years, p=0.003), more frequently postmenopausal patients (57.1% vs. 12.1%, p=0.003), and were more often >10 cm (61.5% vs. 25.8%, p=0.04). Postoperative complications occurred in 8.3%, and no recurrences were observed during follow-up. Conclusion: NEOTs, though rare, accounted for a relatively high proportion of ovarian tumors in our series. They were predominantly benign and diagnosed at an early stage, with favorable outcomes. Conservative surgery should be prioritized in young women to preserve fertility. This study represents the first Tunisian series addressing all histological subtypes of NEOTs and provides a reference for future multicenter research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.